Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Beta Bionics, Inc.NASDAQ: BBNX
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue rises 79.7% from a year ago
Deferred revenue stood at $1.71M at the end of Q1 FY2026, up 79.7% from a year earlier and up 9.5% from the prior quarter.
Context
- Deferred revenue amounted to 0.6% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Deferred revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps rising in the next quarterly balance sheet after a +79.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 1.56M USD
- Year-over-year change
- +65.8%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.56M | +65.8% |
| FY2024 | 2024-12-31 | 939K | +979.3% |
| FY2023 | 2023-12-31 | 87K | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +79.7% is the highest of 5, against a peer median of -59.2%.
- Deferred revenue amounts to 0.6% of total assets for BBNX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $11.53M USD | -2.0% | +106.8% | 1.5% | |
| Mar 2026 | $8.95M USD | -18.4% | -20.3% | 0.8% | |
| Mar 2026 | $1.71M USD | +79.7% | — | 0.6% | |
| Mar 2026 | $1.47M USD | — | +0.3% | 0.5% | |
| Jun 2026 | DKK 0 DKK | — | — | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | -8.6% | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | -4.6% | 0.0% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding BBNX) | — | -59.2% | -4.6% | 0.0% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.